Literature DB >> 588422

Development and application of a radioimmunoassay for methotrexate.

G W Aherne, E M Piall, V Marks.   

Abstract

An antiserum to methotrexate has been produced in a sheep against a conjugate of ovalbumin and methotrexate (MTX) prepared using a water-soluble carbodiimide. The antibodies produced were specific for substances containing the 2,4-diamino pteridine structure. Naturally occurring folates did not interfere with the assay. A radioimmunoassay has been developed using this antiserum, which can be used to measure MTX concentrations of less than 1 ng/ml in biological samples without prior extraction. The concentrations of MTX in the blood and urine of patients following a single i.v. bolus injection and following oral administration of the drug have been measured. The published radioimmunoassays for MTX have been compared.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 588422      PMCID： PMC2025394          DOI： 10.1038/bjc.1977.238

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  20 in total

1.  A fluorometric method for the measurement of 4-amino-10-methyl pteroylglutamic acid (amethopterin) in plasma.

Authors:  M V FREEMAN
Journal:  J Pharmacol Exp Ther       Date:  1957-05       Impact factor: 4.030

2.  Persistence of amethopterin in normal mouse tissues.

Authors:  J R FOUNTAIN; D J HUTCHISON; G B WARING; J H BURCHENAL
Journal:  Proc Soc Exp Biol Med       Date:  1953-06

3.  Radioimmunoassay for methotrexate.

Authors:  L Levine; E Powers
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1974-11

4.  A radio-enzymatic assay for folic acid.

Authors:  S P Rothenberg
Journal:  Nature       Date:  1965-06-12       Impact factor: 49.962

5.  The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man.

Authors:  E S Henderson; R H Adamson; V T Oliverio
Journal:  Cancer Res       Date:  1965-08       Impact factor: 12.701

6.  Radioimmunoassay of methotrexate in biological fluids.

Authors:  C Bohuon; F Duprey; C Boudene
Journal:  Clin Chim Acta       Date:  1974-12-17       Impact factor: 3.786

7.  Pharmacokinetics of methotrexate.

Authors:  D H Huffman; S H Wan; D L Azarnoff; B Hogstraten
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

8.  Plasma levels of methotrexate in cancer patients as studied by an improved spectrophotofluorometric method.

Authors:  J M Kinkade; W R Vogler; P G Dayton
Journal:  Biochem Med       Date:  1974-08

9.  Interspecies correlation of plasma concentration history of methotrexate (NSC-740).

Authors:  R Dedrick; K B Bischoff; D S Zaharko
Journal:  Cancer Chemother Rep       Date:  1970-04

10.  A radioimmunoassay for methotrexate and its comparison with spectrofluorimetric procedures.

Authors:  L J Loeffler; M R Blum; M A Nelsen
Journal:  Cancer Res       Date:  1976-09       Impact factor: 12.701
View more
  11 in total

Review 1.  Clinical pharmacokinetics of methotrexate in children.

Authors:  Y M Wang; T Fujimoto
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

Review 2.  The practical benefits of pharmacokinetics in the use of antineoplastic agents.

Authors:  C Erlichman; R C Donehower; B A Chabner
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

3.  Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia.

Authors:  P J Kearney; P A Light; A Preece; M G Mott
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  A radioimmunoassay for VP16-213 in plasma.

Authors:  G W Aherne; V Marks
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  The effect of timing of a single injection on the toxicity of methotrexate in the rat.

Authors:  J English; G W Aherne; V Marks
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  Small intestinal transit time affects methotrexate absorption in children with acute lymphoblastic leukemia.

Authors:  A D Pearson; A W Craft; E J Eastham; G W Aherne; P Littleton; G L Pearson; A N Campbell
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia.

Authors:  C R Pinkerton; S G Welshman; J G Kelly; R G Shanks; J M Bridges
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

8.  Prolongation and enhancement of serum methotrexate concentrations by probenecid.

Authors:  G W Aherne; E Piall; V Marks; G Mould; W F White
Journal:  Br Med J       Date:  1978-04-29

9.  Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models.

Authors:  G W Aherne; E Ward; N Lawrence; D Dobinson; S J Clarke; H Musgrove; F Sutcliffe; T Stephens; A L Jackman
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

10.  A radioimmunoassay for cytosine arabinoside.

Authors:  E M Piall; G W Aherne; V M Marks
Journal:  Br J Cancer       Date:  1979-10       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.